To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.

Phase 3CompletedNCT00141375

Pfizer132 enrolled

Overview

To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

132

Conditions

Neuropathic Pain

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury. * Must have received study medication under double-blind conditions. Exclusion Criteria: * Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

Locations (7)

Pfizer Investigational Site

Little Bay, New South Wales, Australia

Pfizer Investigational Site

St Leonards, New South Wales, Australia

Pfizer Investigational Site

Warrawong, New South Wales, Australia

Pfizer Investigational Site

Woolloongabba, Queensland, Australia

Outcomes

Primary Outcomes

Safety and Efficacy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.